What Is MOTS-c Studied For? Research Areas, Per the Literature

MOTS-c is not approved by the FDA as a medicine for any condition. This page is not guidance. This page describes what MOTS-c has been studied for in the published literature, not what anyone should do. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or a specific condition.

What MOTS-c Is, in Research Terms

MOTS-c is described in the literature as a mitochondrial-derived peptide, meaning a short peptide encoded within mitochondrial DNA rather than within the nuclear genome. A 2022 review in the Journal of Clinical Investigation placed MOTS-c alongside humanin and the SHLP family as part of a group of mitochondria-derived peptides proposed to act as signalling molecules in aging and healthspan biology (PMID 35499074). A 2019 review in Cell and Tissue Research similarly framed mitochondrial peptides as candidate targets for therapeutic exploration rather than established therapies (PMID 31131430).

The practical consequence of that framing matters for anyone reading about MOTS-c: most of the literature consists of mechanistic cell work, rodent experiments and reviews, plus human observational studies that measured MOTS-c concentrations in blood. A 2023 review in Frontiers in Endocrinology summarised MOTS-c as a promising peptide for therapeutic exploitation, language that signals an early research stage rather than clinical adoption (PMID 36761202).

Background on the peptide itself is collected on the hub page: /learn/mots-c/.

Metabolic Research: Insulin Sensitivity, Glucose Handling and Obesity Models

The largest single research area for MOTS-c is metabolic regulation. A 2023 review in Metabolites gathered preclinical evidence that MOTS-c acts on metabolic homeostasis and described the peptide as functionally preventing metabolic disorders in experimental systems, drawing predominantly on cell and rodent studies rather than clinical trials (PMID 36677050). A 2021 review in Frontiers in Endocrinology covered mitochondrial-derived peptides specifically in diabetes and its complications, and positioned MOTS-c within that literature as a molecule of interest for glucose metabolism and diabetic complications (PMID 35185787).

Reviews in this area consistently note that the supporting work is mechanistic. The 2023 Frontiers in Endocrinology review on MOTS-c described metabolic signalling pathways as the central theme of the peptide's study to date (PMID 36761202), and the 2022 Journal of Clinical Investigation review discussed mitochondria-derived peptides as putative regulators of metabolic and age-related processes (PMID 35499074). No study in this verified set reported a completed randomised clinical trial in which MOTS-c was administered to people with type 2 diabetes or obesity.

Gestational Diabetes Models

One of the more specific metabolic questions studied is gestational diabetes. A 2022 study in Pharmacological Research examined MOTS-c in gestational diabetes mellitus and reported that the peptide relieved hyperglycemia and insulin resistance in that experimental setting, work carried out in laboratory models of the condition rather than as a treatment trial in pregnant patients (PMID 34798268). Researchers in that report framed MOTS-c as a candidate for further investigation, not as an available intervention.

Aging and Healthspan Research

MOTS-c appears repeatedly in aging biology literature. The 2022 Journal of Clinical Investigation review examined mitochondria-derived peptides in aging and healthspan and summarised their proposed roles in cellular stress responses and metabolic adaptation across model systems (PMID 35499074). The 2019 Cell and Tissue Research review placed mitochondrial peptides, including MOTS-c, in the same conceptual category of age-associated signalling molecules under therapeutic consideration (PMID 31131430).

What these reviews do not contain is a human longevity trial. Neither review reported an interventional study in which MOTS-c was given to older adults and lifespan or healthspan endpoints were measured (PMID 35499074, PMID 31131430). Claims that MOTS-c extends human lifespan are not supported by anything in this citation set.

Exercise, Physical Activity and Vascular Function

A second recurring theme is the relationship between MOTS-c and physical activity. A 2023 review in Pflugers Archiv examined exercise and vascular function in sedentary lifestyles in humans and discussed mitochondrial-derived peptide signalling within that physiological context (PMID 37272982). This line of work is largely about MOTS-c as a measured variable that changes with activity status, rather than MOTS-c as something administered to improve exercise capacity.

That distinction is important. Observing that a peptide concentration moves with exercise is not the same as showing that supplying the peptide reproduces the benefits of exercise, and the 2023 review did not report such an interventional human result (PMID 37272982).

Cardiometabolic Biomarker Research

A 2022 paper in Archives of Cardiovascular Diseases discussed mitochondrial-derived peptides as new markers for cardiometabolic dysfunction, describing their potential value as measurable indicators in human cardiometabolic disease rather than as administered agents (PMID 34972639). Biomarker research is a distinct research use: the question asked is whether circulating levels track disease state, not whether giving the peptide changes outcomes. Readers encountering headlines about MOTS-c and heart health should check which of these two questions a given paper actually addressed (PMID 34972639).

Within the broader mitochondrial peptide family, cardioprotection has been studied more directly for humanin than for MOTS-c. A 2022 paper in Biochimica et Biophysica Acta reviewed a cardio-protective role for humanin in myocardial ischemia-reperfusion, a finding about humanin and not about MOTS-c (PMID 34896254). Conflating family members is a common error in secondary coverage.

Ischemia Reperfusion Injury and Oxidative Stress

A 2025 study in Redox Biology investigated MOTS-c in lung ischemia-reperfusion injury and reported that the peptide attenuated injury through MYH9-dependent nuclear translocation and transcriptional activation of antioxidant genes, a mechanistic preclinical finding generated in laboratory models rather than in patients (PMID 40403491). The study is notable mainly for describing a molecular route by which MOTS-c may influence antioxidant gene expression (PMID 40403491).

Oncology Research: Preclinical Only

A 2024 study in Advanced Science reported that MOTS-c suppressed ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination, a mechanistic result obtained in experimental ovarian cancer models (PMID 39321430). This is early-stage cancer biology. Nothing in this citation set reported a clinical oncology trial of MOTS-c in people with ovarian cancer or any other malignancy, and the 2024 report should be read as hypothesis-generating laboratory work (PMID 39321430).

Musculoskeletal Injury and Athletic Performance

A 2026 review in Sports Medicine assessed the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, a category into which non-approved peptides such as MOTS-c fall (PMID 41966639). Reviews of this type exist precisely because interest in unapproved peptides has outpaced the controlled human evidence base, and the review examined that gap rather than endorsing use (PMID 41966639).

Research Areas at a Glance

Adverse Events and Safety: What Studies Report

The verified literature on this page does not contain a dedicated human safety trial of MOTS-c with systematic adverse event reporting. The 2026 Sports Medicine review examined safety and efficacy across approved and unapproved peptide therapies used in musculoskeletal and performance contexts, and that type of review exists because safety data for unapproved peptides are limited (PMID 41966639). Reviews of mitochondrial peptides have discussed therapeutic potential while describing the field as exploratory, which implies that long-term human tolerability has not been characterised (PMID 31131430, PMID 36761202).

Stated plainly: absence of reported adverse events in preclinical papers is not evidence of safety in people. Rodent and cell experiments are not designed to detect the kinds of problems that human trials look for (PMID 35499074).

Where the Evidence Is Weak or Absent

• Weight loss in humans. Metabolic effects in this citation set were described through preclinical work and reviews, not through human weight loss trials (PMID 36677050).
• Athletic performance enhancement. The 2026 Sports Medicine review covered unapproved peptides in this space rather than demonstrating performance benefit for MOTS-c (PMID 41966639).
• Longevity in people. Aging literature on mitochondria-derived peptides remained mechanistic and observational in this set (PMID 35499074).
• Cancer treatment. The ovarian cancer finding was a laboratory mechanism report, not a clinical result (PMID 39321430).
• Cardiac protection specifically by MOTS-c. The ischemia-reperfusion cardioprotection review in this set concerned humanin, a different mitochondrial peptide (PMID 34896254).

How to Read Claims About MOTS-c

Three questions separate a reliable summary from an overstated one. First, was MOTS-c measured or administered? Biomarker papers measure it (PMID 34972639). Second, what was the model: cells, rodents or people? Most mechanistic results in this set came from non-human systems (PMID 40403491). Third, is the source a primary study or a review summarising others, since reviews such as the 2023 Frontiers in Endocrinology paper aggregate findings and use forward-looking language about therapeutic exploitation (PMID 36761202).

MOTS-c is not approved by the FDA as a medicine for any condition. This page is not guidance. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision. Further background is available at /learn/mots-c/.

References

• Mitochondria-derived peptides in aging and healthspan (The Journal of Clinical Investigation, 2022)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation (Frontiers in Endocrinology, 2023)
• Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination (Advanced Science, 2024)
• The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus (Pharmacological Research, 2022)
• Mitochondrial-Derived Peptides in Diabetes and Its Complications (Frontiers in Endocrinology, 2021)
• Mitochondrial peptides-appropriate options for therapeutic exploitation (Cell and Tissue Research, 2019)
• Cardio-protective role of Humanin in myocardial ischemia-reperfusion (Biochimica et Biophysica Acta. General Subjects, 2022)
• MOTS-c Functionally Prevents Metabolic Disorders (Metabolites, 2023)
• MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes (Redox Biology, 2025)
• Mitochondrial-derived peptides: New markers for cardiometabolic dysfunction (Archives of Cardiovascular Diseases, 2022)
• Exercise and vascular function in sedentary lifestyles in humans (Pflugers Archiv, 2023)